Evolution of controlling diabetic retinopathy: Changing trends in the management of diabetic macular EDEMA at a single institution over the past decade

Retina

Volumn 35, Issue 5, 2015, Pages 929-934

  Jusufbegovic, Denis ^a   Mugavin, Mark O ^a   Schaal, Shlomit ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

anti VEGF; diabetic macular edema; evolution of management; treatment

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ARTICLE; CENTRAL RETINAL THICKNESS; DIABETIC MACULAR EDEMA; HUMAN; INTRAOCULAR PRESSURE; LASER COAGULATION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; RETROSPECTIVE STUDY; VISUAL ACUITY; VISUAL ACUITY CHART; DIABETIC RETINOPATHY; DRUG COMBINATION; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; OPHTHALMOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRENDS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; OPHTHALMOLOGY; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 84929049146     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000438     Document Type: Article

References (21)

1. Ruta LM, Magliano DJ, Lemesurier R, et al. Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries. Diabet Med 2013;30:387-398.
2. Fong DS, Aiello AP, Ferris FL, et al. Diabetic retinopathy. Diabetes Care 2004;27:2540-2553.
3. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1-9.
4. Klein R, Klein BE, Moss SE, et al. The wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-1474.
5. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010;26:1587-1597.
6. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985;103:1796-1806.
7. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609-614.
8. Nguyen QD, Shah SM, Heier JS, et al; READ-2 Study Group. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-2181.
9. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-625.
10. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130: 972-979.
11. Do DV, Nguyen QD, Boyer D, et al; da Vinci Study Group. One-year outcomes of the da Vinci study of VEGF trap-eye in eyes with diabetic macular edema. Ophthalmology 2012;119: 1658-1665.
12. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1449; 1449.e1-10.
13. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-427.
14. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.
15. Jonas JB, Kreissig I, Söfker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
16. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-251.
17. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
18. Brown DM, Nguyen QD, Marcus DM, et al; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-2022.
19. Sivaprasad S, Crosby-Nwaobi R, Heng LZ, et al. Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5). Br J Ophthalmol 2013;97:1177-1180.
20. Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 2013;156:502-510.e2.
21. Hutton D, Newman-Casey PA, Tavag M, et al. Switching to less expensive blindness drug could save medicare part B $18 billion over a ten-year period. Health Aff (Millwood) 2014;33: 931-939.